Special Issue

Animal Models of Neurological Disorders: Where Are We Now? (2nd Edition)

Message from the Guest Editors

Animal models are powerful tools for investigating the key principles and underlying mechanisms of diseases and disorders. This Special Issue will provide experimental evidence, updated views, and new treatment strategies regarding these disorders. Critical discussions on the advantages and limitations of animal models used to mirror these neurological disorders are also welcome. This Special Issue will cover original articles and reviews on every aspect of mammalian and non-mammalian animal models of Parkinson's disease. Alzheimer's disease, epilepsy, Huntington's disease. and schizophrenia. This may include genetic, pharmacological, chemogenetic, and optogenetic models of neurological disorders. In this issue, we also encourage authors to submit work on rare neurological and developmental disorders which affect the brain, spinal cord, or peripheral nerves. Moreover, we encourage submissions on novel tools and methods related to animal models of the abovementioned neurological disorders as well. Tools and methods will only be considered if they are novel, well documented, discussed, and have the potential to be useful to the scientific world.

Guest Editors

Prof. Dr. Marc Ekker

Department of Biology, Faculty of Science, University of Ottawa, Ottawa, ON K1N 6N5, Canada

Dr. Sandesh Panthi

Department of Zoology, Brain Health Research Centre, University of Otago, Dunedin 9016, New Zealand

Deadline for manuscript submissions

closed (15 December 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/170700

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).